Placebo-Controlled Study of Oral Fingolimod in Relapsing Multiple Sclerosis
In this 24-month, randomized trial involving patients with relapsing–remitting multiple sclerosis, oral fingolimod reduced the rates of relapse and disability progression, as compared with placebo. Adverse events reported in patients treated with fingolimod included bradycardia, atrioventricular conduction block, macular edema, elevations in liver-enzyme levels, and mild hypertension.
Related Editorial
|
|
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
In this 12-month trial involving patients with relapsing–remitting multiple sclerosis, oral fingolimod was more effective than intramuscular interferon beta-1a in reducing relapse rates. Adverse events associated with fingolimod included herpesvirus infections (two fatal infections), atrioventricular block, macular edema, skin cancer, and liver-enzyme elevation.
Related Editorial
|
|
Cladribine or Placebo for Relapsing Multiple Sclerosis
In this 96-week, placebo-controlled trial, oral cladribine reduced relapse rates and lowered the risk of sustained disability in patients with relapsing–remitting multiple sclerosis. Patients who were treated with cladribine had large reductions in lymphocyte counts and more infections, including herpes zoster and one death from reactivation of tuberculosis.
Related Editorial
|
|
Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2
Suppressive therapy for herpes simplex virus 2 (HSV-2) has also been shown to reduce the levels of human immunodeficiency virus type 1 (HIV-1). However, in this placebo-controlled trial involving 3408 African couples who were discordant in serologic status for these two viruses, daily treatment with acyclovir did not reduce the frequency of HIV-1 transmission, despite a reduction in HIV-1 RNA levels and a 73% reduction in the occurrence of HSV-2–positive genital ulcers.
|
|
Jet Lag
A 55-year-old physician is planning a trip from Los Angeles to London to attend a scientific conference. His previous trip to Europe was complicated by sleepiness during meetings and difficulty falling asleep and remaining asleep at night. He wants to know what he can do to avoid jet lag. What would you advise?
|
|
Under Pressure
A 25-year-old woman presented to her local hospital with dyspnea. She described a 2-year history of progressive shortness of breath on exertion. Within the previous 3 days, her condition had deteriorated to the point that she was unable to leave her bedroom without having dyspnea.
|
|
Comparative Effectiveness and Health Care Spending Implications for Reform
In this Sounding Board article, the authors argue that health care costs can be reduced without a negative effect on quality by reducing spending on interventions that are not cost-effective.
|